Pfizer Vs. AstraZeneca: Which Is Better For Long-Term Investors?

Trending Articles - Wednesday, Apr 19 Pfizer Vs. AstraZeneca: Which Is Better For Long-Term Investors? By Nathan Aisenstadt Sentiment Speaks: The Next 3 Months Will Tell Us If We Have A Crash Setting Up This Year By Avi Gilburt Nikola: The End Is Near By Simple Investment Ideas Amazon: Get Ready For A Weak Q1 Report By The Asian Investor Boeing: Run, Run For The Hills By Trapping Value Medical Properties Trust: Focus Upon What Is Important By Long Player Salesforce: Quickly Becoming A Cash Flow Story By Julian Lin Tesla Q1 Earnings Preview: Short-Term Pain, Long-Term Gain By Stocks and Savings Amazon Stock: You Have Been Pumped And Warned By Andy Jassy By Ahan Vashi Google: Samsung And Apple Deal Facing Major Risks By JR Research Most Popular Charles Schwab: Results Should Encourage Bears By Trapping Value Tesla Stock: What You Need To Know About Q1 Earnings By Beth Kindig Exxon Mobil Corporation And XLE: Kevin O'Leary Is Right, Energy Is Golden By Envision Research FEATURED: Empower your investing this earnings season Earnings season can spark serious volatility. But there's also plenty of opportunity to find quality stocks with a strong long-term outlook. Drive winning decisions with Seeking Alpha Premium - now for only $4.95 for your first month! (Automatically renews at $239/year.) Go Premium now » Download the Seeking Alpha App! Like our Morning Briefing? Try our other newsletters as well. This email was sent to you because you signed up to receive Morning Briefing. If you do not want to receive Morning Briefing emails, click here to unsubscribe. Sent by Seeking Alpha, 234 5th Ave, 5th floor, New York, NY 10001